Affiliation:
1. N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Abstract
Acute lymphoblastic leukemia is the most common tumor of childhood. Using of modern treatment chemotherapy regimens, we can reach about 90 % of 5-year survival. An important problem – patients with relapses of the disease, as well as children with the persistence of minimal residual disease (MRD), which is absolutely necessary in hematopoietic stem cell transplantation aspects. The possibilities of continuous intensive chemotherapy are limited by high toxicity, and therefore targeted drugs are used to achieve MRD-negative remission in children, in particular, a bispecific antibody – blinatumomab.This article presents our own experience of using blinatumomab in patients using various financial sources, the technical features of using within the federal medical center. Also, undesirable effects of the drug and their therapy are mentioned.
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献